IL6 and non-small cell lung carcinoma: Evidence from epidemiological studies is accruing in favor of a contributory role of elevated circulating IL-6 in patients with advanced tumor stages of various cancers, such as non-small cell lung cancer, colorectal cancer and renal cell carcinoma86, 87, 88.